Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
26 août 2020 18h05 HE
|
Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...